Overview

Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer

Status:
Recruiting

Trial end date:
2023-12-31

Target enrollment:

Participant gender:

Summary

This is an open-label, Phase 1b study to evaluate the safety and tolerability of IDX-1197 and determine the MTD and RP2D in combination with XELOX or irinotecan in patients with advanced gastric cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Idience Co., Ltd.

Treatments:

Irinotecan